| 名称 | AKT2 E17K/BaF3 |
| 型号 | CBP73281 |
| 报价 |  |
| 特点 | AKT2 E17K/BaF3,母细胞：BaF3；冻存条件：90% FBS+10% DMSO； |
产品搜索
相关文章
联系我们
联系人：蒋经理
电话：4008750250
号码：
手机：18066071954
地址：南京市栖霞区纬地路9号
Email： zhangxiangwen@cobioer.com
电话：4008750250
号码：
手机：18066071954
地址：南京市栖霞区纬地路9号
Email： zhangxiangwen@cobioer.com
产品展示 / PRODUCTS
药靶细胞株 > kinase激酶细胞株 > CBP73281AKT2 E17K/BaF3
- 详细内容
| CBP73281 | |
| I. Introduction | |
Cell Line Name： | AKT2 E17K/BaF3 |
Host Cell: | Ba/F3 |
| Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS |
Mycoplasma Status: | Negative |
II. Background | |
| V-akt murine thymoma viral oncogene homolog 2 (AKT2) is a gene that encodes a protein serine/threonine kinase with a SH2-like domain. Missense mutations, nonsense mutations, silent mutations, and in-frame deletions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer. AKT2 is altered in 1.54% of all cancers with lung adenocarcinoma, breast invasive ductal carcinoma, pancreatic adenocarcinoma, high grade ovarian serous adenocarcinoma, and colon adenocarcinoma having the greatest prevalence of alterations.The most common alterations in AKT2 are AKT2 Amplification (0.96%), AKT2 Mutation (0.61%), AKT2 Loss (0.09%), AKT2 E17K (0.04%), and AKT2 Fusion (0.05%) . | |
III. Representative Data | |
1.WB of AKT2 E17K/BaF3
| |
2. Anti-proliferation assay | |
Figure 2. CTG Proliferation Assay of BaF3 AKT2 E17K Cells (C4). | |
